top of page
Home: Welcome
OUR COMPANY
Harnessing evolution for genetic reprogramming of immune cells in the body
We are providing solutions to two main hurdles in cell therapy for solid tumors
Autologous CAR-T manufacturing is inefficient and costly
Current Autologous Cell Therapy
Supercharged In Vivo Cell Therapy™
T cell isolation from Patient's Blood
CAR-T Engineering
CAR-T Expansion
Re-infusion to patients
Vector Injection
In situ engineering
Tumor killing
Tumor killing
Complex manufacturing and lymphodepletion required
Simplified manufacturing and no lymphodepletion
Allowing our own body to produce the therapy.
Multiple barriers exist in solid tumors
Immunosuppressive tumor microenvironment
Reduced potency
Exhaustion / lack of persistence
Inefficient manufacturing (lack of stemness)
Poor tumor infiltration
Evolving immune cells for overcoming obstacles in solid tumors.
We apply principles of evolution to tackle the toughest questions in solid tumors.
scFv Evolution: Discover novel targets and specific scFvs for solid tumors
.png)
Vector Evolution: Engineer vector to enhance delivery, safety, and specificity.
CAR Evolution: Design and optimize CAR architecture for enhanced T cell function
Genomic Evolution: Incorporate with novel genetic enhancements to overcome barriers in solid tumors.
bottom of page